When you boil it all down, the board of directors decides on a company's dividend policy. It is entirely up to this group. Obviously, they don't work in a vacuum. The board consults with a company's ...

Pfizer showcased multiple late-breakers at the American Society of Clinical Oncology’s annual conference but its biggest data are expected later this year. Pfizer arrived in Chicago this weekend for ...

Pfizer is paying Innovent $650 million upfront to partner on cancer drug development, following Bristol Myers Squibb by striking a broad pact that positions Pfizer to leverage China’s fast early ...

Pfizer is dealing with some headwinds. The drop in demand for COVID vaccines is just one example of the issues management is dealing with. Another is a series of upcoming patent cliffs, when generic ...

Pfizer paid $9.771 billion in dividends in FY2025 against free cash flow of just $9.076 billion, meaning the dividend exceeded free cash flow by $695 million. When a company pays out more than it ...

Pfizer is eyeing an earlier use of its PARP inhibitor Talzenna after a positive phase 3 trial in metastatic hormone-sensitive prostate cancer (mHSPC). The phase 3 Talapro-3 trial met its primary ...

Robotic Process Automation (RPA) uses automated bots to emulate human actions in digital systems, usually focused on handling repetitive tasks such as data entry. Many of the world’s largest ...

Pfizer reaffirmed it is a household name through its partnership with BioNTech on the Pfizer-BioNTech COVID-19 vaccine, which received its first U.S. authorization ...

Pfizer said its experimental obesity drug, which it acquired through Metsera, drove solid weight loss when taken once a month in a mid-stage trial. The data offer early evidence that the injection can ...

Novavax secures a non-exclusive licensing deal with Pfizer, validating Matrix-M's platform value and shifting NVAX toward a technology provider model. NVAX receives $30M upfront, a potential $500M in ...

Novavax has agreed to a deal to let Pfizer use Matrix-M adjuvant in its products for an upfront payment of $30 million and up to another $500 million in milestone payments. The biotech company said ...

Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine programs. The tech, called Matrix-M, is designed to trigger an immune ...